239 related articles for article (PubMed ID: 30260324)
1. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
Ren Y; Bi C; Zhao X; Lwin T; Wang C; Yuan J; Silva AS; Shah BD; Fang B; Li T; Koomen JM; Jiang H; Chavez JC; Pham LV; Sudalagunta PR; Wan L; Wang X; Dalton WS; Moscinski LC; Shain KH; Vose J; Cleveland JL; Sotomayor EM; Fu K; Tao J
J Clin Invest; 2018 Dec; 128(12):5517-5530. PubMed ID: 30260324
[TBL] [Abstract][Full Text] [Related]
2. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
3. The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.
Oon ML; Hoppe MM; Fan S; Phyu T; Phuong HM; Tan SY; Hue SS; Wang S; Poon LM; Chan HLE; Lee J; Chee YL; Chng WJ; de Mel S; Liu X; Jeyasekharan AD; Ng SB
Leuk Lymphoma; 2019 Dec; 60(13):3214-3224. PubMed ID: 31259656
[TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of a novel MYC/BCL2 "double-hit" diffuse large B cell lymphoma cell line, RC.
Pham LV; Lu G; Tamayo AT; Chen J; Challagundla P; Jorgensen JL; Medeiros LJ; Ford RJ
J Hematol Oncol; 2015 Oct; 8():121. PubMed ID: 26515759
[TBL] [Abstract][Full Text] [Related]
5. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
[TBL] [Abstract][Full Text] [Related]
6. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
[TBL] [Abstract][Full Text] [Related]
7. The role of aurora A and polo-like kinases in high-risk lymphomas.
Murga-Zamalloa C; Inamdar KV; Wilcox RA
Blood Adv; 2019 Jun; 3(11):1778-1787. PubMed ID: 31186254
[TBL] [Abstract][Full Text] [Related]
8. PLK1: a promising and previously unexplored target in double-hit lymphoma.
Hassan QN; Alinari L; Byrd JC
J Clin Invest; 2018 Dec; 128(12):5206-5208. PubMed ID: 30395539
[TBL] [Abstract][Full Text] [Related]
9. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
10. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
Mu X; Bai L; Xu Y; Wang J; Lu H
Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
[TBL] [Abstract][Full Text] [Related]
11. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
Hugle M; Belz K; Fulda S
Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389
[TBL] [Abstract][Full Text] [Related]
12. Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma.
Feng Y; Lin J; Liu Y; Tang Y; Zhou Y; Zhong M
Int J Exp Pathol; 2019 Feb; 100(1):32-40. PubMed ID: 30912195
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
14. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
Mai J; Zhong ZY; Guo GF; Chen XX; Xiang YQ; Li X; Zhang HL; Chen YH; Xu XL; Wu RY; Yu Y; Li ZL; Peng XD; Huang Y; Zhou LH; Feng GK; Guo X; Deng R; Zhu XF
Theranostics; 2019; 9(12):3541-3554. PubMed ID: 31281496
[No Abstract] [Full Text] [Related]
15. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
16. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
17. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.
Shi JQ; Lasky K; Shinde V; Stringer B; Qian MG; Liao D; Liu R; Driscoll D; Nestor MT; Amidon BS; Rao Y; Duffey MO; Manfredi MG; Vos TJ; D' Amore N; Hyer ML
Mol Cancer Ther; 2012 Sep; 11(9):2045-53. PubMed ID: 22609854
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer.
Li J; Ohmura S; Marchetto A; Orth MF; Imle R; Dallmayer M; Musa J; Knott MML; Hölting TLB; Stein S; Funk CM; Sastre A; Alonso J; Bestvater F; Kasan M; Romero-Pérez L; Hartmann W; Ranft A; Banito A; Dirksen U; Kirchner T; Cidre-Aranaz F; Grünewald TGP
Nat Commun; 2021 Sep; 12(1):5356. PubMed ID: 34531368
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.
Yu Z; Deng P; Chen Y; Liu S; Chen J; Yang Z; Chen J; Fan X; Wang P; Cai Z; Wang Y; Hu P; Lin D; Xiao R; Zou Y; Huang Y; Yu Q; Lan P; Tan J; Wu X
Adv Sci (Weinh); 2021 Dec; 8(23):e2100759. PubMed ID: 34881526
[TBL] [Abstract][Full Text] [Related]
20. Targeting MYC and BCL2 by a natural compound for "double-hit" lymphoma.
Liu X; Xu S; Zhang J; Fan M; Xie J; Zhang B; Li H; Yu G; Liu Y; Zhang Y; Song J; Horne D; Chan WC; Chu X; Huang W
Hematol Oncol; 2022 Aug; 40(3):356-369. PubMed ID: 35482553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
